SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Draisma G, Etzioni R, Tsodikov A et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 2009; 101: 37483
  • 2
    Etzioni R, Penson DF, Legler JM et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002; 94: 98190
  • 3
    Gosselaar C, Roobol MJ, Schroder FH. Prevalence and characteristics of screen-detected prostate carcinomas at low prostate-specific antigen levels: aggressive or insignificant? BJU Int 2005; 95: 2317
  • 4
    Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010; 28: 12631
  • 5
    van den Bergh RC, Roemeling S, Roobol MJ et al. Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol 2009; 55: 18
  • 6
    Stattin P, Holmberg E, Johansson JE, Holmberg L, Adolfsson J, Hugosson J. Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst 2010; 102: 9508
  • 7
    Kattan MW, Eastham JA, Wheeler TM et al. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 2003; 170: 17927
  • 8
    Steyerberg EW, Roobol MJ, Kattan MW, van der Kwast TH, de Koning HJ, Schroder FH. Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol 2007; 177: 10712; discussion 112
  • 9
    Dong F, Kattan MW, Steyerberg EW et al. Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice. J Urol 2008; 180: 1504
  • 10
    Bul MDN, Steyerberg EW, de la Roza G et al. Updating the prostate cancer risk indicator for contemporary biopsy schemes. Can J Urol 2011; 18: 56259
  • 11
    Razavi D, Gandek B. Testing Dutch and French translations of the SF-36 Health Survey among Belgian angina patients. J Clin Epidemiol 1998; 51: 97581
  • 12
    van der Bij AK, de Weerd S, Cikot RJ, Steegers EA, Braspenning JC. Validation of the dutch short form of the state scale of the Spielberger State-Trait Anxiety Inventory: considerations for usage in screening outcomes. Community Genet 2003; 6: 847
  • 13
    van den Bergh RC, Korfage IJ, Borsboom GJ, Steyerberg EW, Essink-Bot ML. Prostate cancer-specific anxiety in Dutch patients on active surveillance: validation of the memorial anxiety scale for prostate cancer. Qual Life Res 2009; 18: 10616
  • 14
    Koedoot N, Molenaar S, Oosterveld P et al. The decisional conflict scale: further validation in two samples of Dutch oncology patients. Patient Educ Couns 2001; 45: 18793
  • 15
    Beekman AT, van Limbeek J, Deeg DJ, Wouters L, van Tilburg W. A screening tool for depression in the elderly in the general population: the usefulness of Center for Epidemiological Studies Depression Scale (CES-D). Tijdschr Gerontol Geriatr 1994; 25: 95103
  • 16
    Sanderman R, Arindell WA, Ranchor AV, Eysenck HJ, Eysenck SBG. Het Meten Van Persoonlijkheidskenmerken Met De Eysenck Personality Questionnaire (EPQ): Een Handleiding. Noordelijk Centrum Voor Gezondheidsvraagstukken. Groningen, The Netherlands: Rijksuniversiteit Groningen, 1995
  • 17
    van Vugt HA, Roobol MJ, Venderbos LD et al. Informed decision making on PSA testing for the detection of prostate cancer: an evaluation of a leaflet with risk indicator. Eur J Cancer 2010; 46: 66977
  • 18
    van den Bergh RC, van Vugt HA, Korfage IJ et al. Disease insight and treatment perception of men on active surveillance for early prostate cancer. BJU Int 2009; 105: 3228
  • 19
    Roth A, Nelson CJ, Rosenfeld B et al. Assessing anxiety in men with prostate cancer: further data on the reliability and validity of the Memorial Anxiety Scale for Prostate Cancer (MAX-PC). Psychosomatics 2006; 47: 3407
  • 20
    Roberts RE, Vernon SW. The Center for Epidemiologic Studies Depression Scale: its use in a community sample. Am J Psychiatry 1983; 140: 416
  • 21
    Eysenck HJ, Eysenck SBG. Manual of the Eysenck Personality Scales (EPS Adults). London, UK: Hodder & Stoughton, 1991
  • 22
    Steginga SK, Occhipinti S, Gardiner RA, Yaxley J, Heathcote P. Making decisions about treatment for localized prostate cancer. BJU Int 2002; 89: 25560
  • 23
    Gwede CK, Pow-Sang J, Seigne J et al. Treatment decision-making strategies and influences in patients with localized prostate carcinoma. Cancer 2005; 104: 138190
  • 24
    Gorin MA, Soloway CT, Eldefrawy A, Soloway MS. Factors That Influence Patient Enrollment in Active Surveillance for Low-risk Prostate Cancer. Urology 2011; 77: 58891
  • 25
    Zeliadt SB, Ramsey SD, Penson DF et al. Why do men choose one treatment over another?: a review of patient decision making for localized prostate cancer. Cancer 2006; 106: 186574
  • 26
    van den Bergh RC, Essink-Bot ML, Roobol MJ et al. Anxiety and distress during active surveillance for early prostate cancer. Cancer 2009; 115: 386878
  • 27
    Reilly BM, Evans AT. Translating clinical research into clinical practice: impact of using prediction rules to make decisions. Ann Intern Med 2006; 144: 2019
  • 28
    Hunink MGM, Glasziou PP, Siegel JE et al. Decision Making in Health and Medicine: Integrating Evidence and Values. Cambridge, UK: Cambridge University Press, 2001
  • 29
    Boevee SJ, Venderbos LD, Tammela TL et al. Change of tumour characteristics and treatment over time in both arms of the European Randomized study of Screening for Prostate Cancer. Eur J Cancer 2010; 46: 30829
  • 30
    Brehaut JC, Stiell IG, Graham ID. Will a new clinical decision rule be widely used? The case of the Canadian C-spine rule. Acad Emerg Med 2006; 13: 41320